 NEW YORK, Aug. 11, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast cells by mutating the messenger RNA mRNA before it can deliver instructions for manufacturing the gene responsible for cell proliferation. Current treatments for mast cell cancers target signaling from the receptor encoded by the c-KIT gene, and the efficacy of current therapies can be negatively affected by c-KIT mutations associated with disease development, says Glenn Cruse, assistant professor of immunology at North Carolina State University and a Scientific Advisor to Hoth and corresponding author of the research. 